Home>>Signaling Pathways>> Proteases>> Drug Metabolite>>Niraparib metabolite M1 (Niraparib carboxylic acid metabolite M1)

Niraparib metabolite M1 (Niraparib carboxylic acid metabolite M1)

Catalog No.GC33452

Niraparib metabolite M1 (Niraparib carboxylic acid metabolite M1) is a metabolite of niraparib, and the latter one acts as a novel poly(ADP-Ribose) polymerase (PARP) inhibitor.

Products are for research use only. Not for human use. We do not sell to patients.

Niraparib metabolite M1 (Niraparib carboxylic acid metabolite M1) Chemical Structure

Cas No.: 1476777-06-6

Size Price Stock Qty
10mM (in 1mL DMSO)
$357.00
In stock
1mg
$138.00
In stock
5mg
$506.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Niraparib metabolite M1 is a metabolite of niraparib, and the latter one acts as a novel poly(ADP-Ribose) polymerase (PARP) inhibitor.

Niraparib metabolite M1 has the validation in plasma and urine for the support of clinical studies such as the mass balance study and the absolute bioavailability study[1].

[1]. van Andel L, et al. Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Nov 19;1040:14-21.

Reviews

Review for Niraparib metabolite M1 (Niraparib carboxylic acid metabolite M1)

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Niraparib metabolite M1 (Niraparib carboxylic acid metabolite M1)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.